Danish technology company in the healthcare field successfully secures €1.7 million in funding for expansion within the European Union.
The Danish MedTech startup, VentriJect, has recently secured a €1.7 million funding round to support the expansion of its cardiorespiratory fitness monitoring device. The company, which has gained a foothold in several European markets, is now preparing for entry into the US market, a move that would provide access to over 55,000 health clubs and the world's largest healthcare market [1][2][3].
The funding will be allocated to accelerating expansion in Europe, continuing negotiations with healthcare providers, and making preparations for launching in the US market. This strategic push indicates a broadening of geographic footprint and enhanced adoption in key healthcare sectors, including the American market.
The investment in VentriJect is an indication of growing venture capital (VC) interest in medical technology opportunities in Denmark. The Export and Investment Fund of Denmark (EIFO), one of the largest investors in VentriJect, also recently invested €48 million into the HealthCap IX fund, which focuses on Nordic healthtech [4]. This fund's specific focus on the region's medical technology sector underscores the increasing VC investment in the medical technology sector in the Nordic region [5].
Novo Holdings, a Danish investment company involved in both biotechnology and healthtech investments in Denmark, is another key player in this growing ecosystem. The BioInnovation Institute (BII), funded by Novo Nordisk, supports the growth of the biotechnology scene in Denmark, further fueling the country's reputation as a factory for innovative tech startups [6].
VentriJect's technology, Seisomofit, uses seismocardiography to measure cardiorespiratory fitness (CRF) in under three minutes without exercise. The device's ability to provide a VO2 max estimation quickly and accurately has attracted interest from those seeking healthcare exposure with a lower risk profile [7][8]. Anders Throup-Jensen from EIFO expressed optimism about VentriJect's future as a market leader in VO2 Max measurements.
The startup currently has customers in Denmark, the Netherlands, Sweden, Switzerland, and the UK. With the new funding, VentriJect is poised to expand its reach and make its mark in the US market, a move that could solidify its position as a key player in the global healthtech industry.
References: 1. VentriJect Raises €1.7 Million to Expand Cardiorespiratory Fitness Monitoring Device 2. Danish MedTech Startup VentriJect Secures €1.7 Million Funding 3. VentriJect Prepares for US Market Entry with €1.7 Million Funding 4. Novo Holdings and EIFO Invest €48 Million into HealthCap IX Fund 5. Nordic Region Sees Increase in VC Investment in Medical Technology Sector 6. BioInnovation Institute Supports Growth of Biotechnology Scene in Denmark 7. Medtech Companies Like VentriJect Attracting Lower Risk Investors 8. Seisomofit Provides VO2 Max Estimation in Under Three Minutes Without Exercise
- The investment in VentriJect, a Danish MedTech startup, showcases the rising interest of venture capitalists in financing technological advancements in health-and-wellness, as seen in the €48 million allocated by the Export and Investment Fund of Denmark to the HealthCap IX fund, which focuses on Nordic healthtech.
- The growing popularity of VentriJect's Seisomofit technology, which uses science to measure cardiorespiratory fitness rapidly and accurately, has caught the attention of investors who seek exposure to medical conditions with a lower risk profile in the health-and-wellness and medical technology sectors.
- VentriJect's imminent entry into the US market, which boasts over 55,000 health clubs and the world's largest healthcare market, highlights the startup's strategic business maneuvers and its goal to become a prominent player in the global healthtech industry, as well as extending its geographic footprint into new technological landscapes.
